Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting

• Published in: Biochemistry and biophysics reports Vol. 17; pp. 197 - 207
• Main Authors: Hatami, Elham, Mu, Ying, Shields, Deanna N, Chauhan, Subhash C, Kumar, Santosh, Cory, Theodore J, Yallapu, Murali M
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier 01.03.2019
• Subjects: Nanoparticles; Mannose; HIV; Cancer; Macrophage
• ISSN: 2405-5808; 2405-5808
• DOI: 10.1016/j.bbrep.2019.01.007

Our goal was to design nanocarriers that specifically target and deliver therapeutics to polarized macrophages. Mannose receptors are highly overexpressed on polarized macrophages. In this study, we constructed Pluronic® -F127 polymer and tannic acid (TA) based nanoparticles (F127-TA core nanoparticles) with varying mannose densities. The particle size of the optimized mannose-decorated F127-TA hybrid nanoparticles (MDNPs) was found to be ~ 265 nm with a negative zeta potential of ~ - 4.5 mV. No significant changes in the size and zeta potentials of nanoparticles were observed, which demonstrated structural integrity and stability of the nanoformulation. Physicochemical characteristics of MDNPs were evaluated by FTIR and TGA and demonstrated the presence of mannose units on surface nanoparticles. A mannose-dependent cellular targeting and uptake of MDNPs was found in U937 macrophages. The uptake process was found to vary directly with time and volume of MDNPs nanoparticles. The uptake pattern is higher in M2 than M1. This behavior was also evident from the instantaneous and superior binding profile of M2 macrophage lysate protein with MDNPs over that of M1 macrophage lysate protein. These results demonstrated that an appropriate mannose ligand density was confirmed, suggesting efficient targeting of M2. Altogether, these data support that the MDNPs formulation could serve as a targeted therapeutic guide in the generation of nanomedicine to treat various conditions as an anti-inflammation therapy.